UA88294C2 - Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation - Google Patents

Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Info

Publication number
UA88294C2
UA88294C2 UAA200610138A UAA200610138A UA88294C2 UA 88294 C2 UA88294 C2 UA 88294C2 UA A200610138 A UAA200610138 A UA A200610138A UA A200610138 A UAA200610138 A UA A200610138A UA 88294 C2 UA88294 C2 UA 88294C2
Authority
UA
Ukraine
Prior art keywords
cancer
antibodies
methods
cancer cell
cell proliferation
Prior art date
Application number
UAA200610138A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ванита Рамакришнан
Винай Бхаскар
Суй Хо
Ричард Муррей
Дебби Ло
Original Assignee
Фейсит Биотек Корпорейшен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фейсит Биотек Корпорейшен filed Critical Фейсит Биотек Корпорейшен
Publication of UA88294C2 publication Critical patent/UA88294C2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for direct killing of cancer cells using anti- α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.
UAA200610138A 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation UA88294C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55642104P 2004-03-24 2004-03-24

Publications (1)

Publication Number Publication Date
UA88294C2 true UA88294C2 (en) 2009-10-12

Family

ID=37879292

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200610138A UA88294C2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Country Status (3)

Country Link
CN (1) CN1933851B (en)
UA (1) UA88294C2 (en)
ZA (1) ZA200607849B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130091745A (en) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
JP2022513693A (en) * 2018-11-29 2022-02-09 ハーバー・バイオメド・セラピューティクス・リミテッド Anti-PD-L1 antibody preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis

Also Published As

Publication number Publication date
ZA200607849B (en) 2007-12-27
CN1933851A (en) 2007-03-21
CN1933851B (en) 2011-09-14

Similar Documents

Publication Publication Date Title
HK1101348A1 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
EP1708752A4 (en) Polymer-bound antibody cancer therapeutic agent
EA200601433A1 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF TUMORS AND METASTASIS
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DE602005027617D1 (en) RADIO THERAPY TREATMENT MONITORING USING ULTRASOUND
EA200801853A1 (en) EFFECTIVE PEPTIDES IN THE TREATMENT OF TUMORS AND OTHER DISEASES THAT REQUIRE REMOVAL OR DESTRUCTION OF CELLS
MX2009006779A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors.
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2006097743A3 (en) Method for actvating natural killer cells by tumor cell preparation in vitro
WO2004000094A8 (en) Predictive markers in cancer therapy
MX2019015200A (en) Diarylhydantoin compounds.
ATE512146T1 (en) PHENYLUREA DERIVATIVES AS INHIBITORS OF TYROSINE KINASES FOR THE TREATMENT OF TUMOR DISEASES
DE60027768D1 (en) TREATMENT OF METASTATIC DISEASE
WO2005017493A3 (en) Biomarkers in cancer
DE602005023488D1 (en) TUMOR ASSOCIATED ANTIGEN PROFILES IN CANCER DIAGNOSIS AND IMMUNOTHERAPY
TW200626900A (en) Wnt proteins and detection and treatment of cancer
ATE526037T1 (en) METHOD FOR KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS
WO2008083326A3 (en) Targeting of ews-fli1 as anti-tumor therapy
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
MX2019015194A (en) Compositions and methods for cancer therapy with dengue virus and dendritic cells.
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
DE60038624D1 (en) METHODS OF TREATING SOLID TUMORS AND METASTASES WITH GENE THERAPY
UA88294C2 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
MXPA02011563A (en) Compositions and methods for the therapy and diagnosis of breast cancer.